No information is available on the clinical use of palbociclib during breastfeeding. Because palbociclib is 85% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 29 hours and the manufacturer recommends that breastfeeding be discontinued during palbociclib therapy and for 3 weeks after the last dose. Palbociclib is also given in combination with letrozole or fulvestrant, which may increase the risk to the infant.
关于哌柏西利在母乳喂养期间的临床应用尚无可用信息。由于哌柏西利与血浆蛋白的结合率为85%，其在乳汁中的含量可能较低。然而，其半衰期约为29小时，制造商建议在哌柏西利治疗期间及最后一剂后3周内停止母乳喂养。哌柏西利也与来曲唑或氟维司群联合使用，这可能会增加对婴儿的风险。
